CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse (Q40726923)

23 September 2017

title

CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse (English)

1 reference

23 September 2017

0 references

1 reference

hepatocellular carcinoma

1 reference

0 references

1 reference

Wei Zhu

1 reference

23 September 2017

Kun Xie

1 reference

23 September 2017

Yuanjian Xu

1 reference

23 September 2017

Le Wang

1 reference

23 September 2017

Kaiming Chen

1 reference

23 September 2017

Longzhen Zhang

1 reference

23 September 2017

Jianmin Fang

1 reference

23 September 2017

publication date

2 April 2016

1 reference

23 September 2017

1 reference

23 September 2017

volume

217

1 reference

23 September 2017

page(s)

125-132

1 reference

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Multiplex genome engineering using CRISPR/Cas systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

HBVdb: a knowledge database for Hepatitis B Virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Control of hepatitis B virus at the level of transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

CRISPR-Cas systems for editing, regulating and targeting genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Hepatitis B virus: significance of genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Targeting Hepatitis B Virus With CRISPR/Cas9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Using defined finger-finger interfaces as units of assembly for constructing zinc-finger nucleases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.04.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2016.04.003

1 reference

23 September 2017

1 reference